![](/img/cover-not-exists.png)
Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications
Jean-François Baladi, Peter A.B. Bailey, Sandra Black, Rémi W. Bouchard, Karl D. Farcnik, Serge Gauthier, Andrew Kertesz, Erich Mohr, Alain RobillardVolume:
22
Year:
2000
Language:
english
DOI:
10.1016/s0149-2918(00)83053-2
File:
PDF, 957 KB
english, 2000